Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series

Goel, Mishita; Varandani, Rajiv; Okwuosa, Tochukwu

doi:10.1186/s40959-020-00071-x

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RAAS inhibitors also developed hypertension resistance in cancer patients to control blood pressure. Thus, the efficacy of RAAS inhibitors in blood pressure control in cancer therapy is still unclear . The above-mentioned negative impacts of these drugs reduce the optimism for their use in cancer treatment.…”

Section: Repurposing Of Cvs Drugs For Prostate Cancer Treatmentmentioning

confidence: 99%

“…Thus, the efficacy of RAAS inhibitors in blood pressure control in cancer therapy is still unclear. 127 The above-mentioned negative impacts of these drugs reduce the optimism for their use in cancer treatment. Moreover, drug repurposing also faces huge challenges like shorter patent duration (3 years) and low return on investment.…”

Section: Repurposing Of Cvs Drugs For Prostate Cancer Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new incidences in 2018. An increase in incidences is an issue of concern that should be addressed. Of all the reported prostate cancers, 85% were detected in stages III and IV, making them difficult to treat. Conventional drugs gradually lose their efficacy due to the developed resistance against them, thus requiring newer therapeutic agents to be used as monotherapy or combination. Recent research regarding treatment options has attained remarkable speed and development. Therefore, in this context, drug repurposing comes into the picture, which is defined as the "investigation of the off-patent, approved and marketed drugs for a novel therapeutic indication" which saves at least 30% of the time and cost, reducing the cost of treatment for patients, which usually runs high in cancer patients. The anticancer property of cardiac glycosides in cancers was tested in the early 1980s. The trend then shifts toward treating prostate cancer by repurposing other cardiovascular drugs. The current review mainly emphasizes the advantageous antiprostate cancer profile of conventional CVS drugs like cardiac glycosides, RAAS inhibitors, statins, heparin, and beta-blockers with underlying mechanisms.

show abstract

Section: Repurposing Of Cvs Drugs For Prostate Cancer Treatmentmentioning

confidence: 99%

Section: Repurposing Of Cvs Drugs For Prostate Cancer Treatmentmentioning

confidence: 99%